Get the Stockscreener App
5.68
1.22%
-0.07
After Hours:
5.70
0.02
+0.35%
Abeona Therapeutics Inc stock is traded at $5.68, with a volume of 948.82K.
It is down -1.22% in the last 24 hours and down -8.97% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$5.75
Open:
$5.79
24h Volume:
948.82K
Relative Volume:
0.59
Market Cap:
$318.19M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-2.2016
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
-2.24%
1M Performance:
-8.97%
6M Performance:
+1.25%
1Y Performance:
+33.96%
1-Day Range:
$5.635
$5.80
1-Week Range:
$5.635
$6.03
52-Week Range:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.68 | 318.19M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics' Zevaskyn Vs. Krystal Biotech's Vyjuvek (KRYS, ABEO) - Seeking Alpha
Trend Tracker for (ABEO) - news.stocktradersdaily.com
ABEONA THERAPEUTICS Executives Sell Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Officer Sells Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Purchased by Bank of America Corp DE - Defense World
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
Abeona Therapeutics at Jefferies Conference: ZivaSkin’s Promising Launch By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Gains "Outperform" Rating from Oppenheimer | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating with Promising Outlook | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating - GuruFocus
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Announces New Employee Inducement Grants - MarketScreener
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Un - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics Awards Stock Grants Worth 11,500 Shares: New Employee Compensation Details Revealed - Stock Titan
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Abeona Therapeutics® to Present at the Jefferies Global Healthca - GuruFocus
Abeona Therapeutics Inc. CEO and CCO to Speak at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Abeona Therapeutics Leadership to Share Latest Company Updates at Major Healthcare Conference - Stock Titan
Trading (ABEO) With Integrated Risk Controls - news.stocktradersdaily.com
Director Cashes In on Abeona Therapeutics Stock! - TipRanks
Insider Sell: Mark Alvino Sells Shares of Abeona Therapeutics In - GuruFocus
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionAbeona Therapeutics (NASDAQ:ABEO), Ascentage Pharma Group (NASDAQ:AAPG) - Benzinga
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Jane Street Group LLC Purchases 118,262 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - PR Newswire
Dystrophic Epidermolysis Bullosa Market Predicted to See - openPR.com
ABEO: Sells Priority Review Voucher for $155 Million… - MSN
Abeona Therapeutics finally expanding to make cell-based gene therapy - The Business Journals
Abeona Therapeutics Elects New Directors at Meeting - TipRanks
ABEO: Sells Priority Review Voucher for 155 Million - Smartkarma
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - MSN
Stifel Nicolaus Issues Pessimistic Forecast for Abeona Therapeutics (NASDAQ:ABEO) Stock Price - Defense World
(ABEO) Trading Report - news.stocktradersdaily.com
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2025 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by StockNews.com - Defense World
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy By Investing.com - Investing.com South Africa
Abeona Therapeutics Reports Improved Financial Performance - TipRanks
Insider Selling: Mark Alvino Sells Shares of Abeona Therapeutics Inc (ABEO) - GuruFocus
Abeona Therapeutics (ABEO) Transitions to Commercial Stage with ZEVASKYN Launch - GuruFocus
Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success - TipRanks
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy - Investing.com Australia
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO St - GuruFocus
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Receives Revised Price Target Amid Po - GuruFocus
Abeona Therapeutics: Q1 Earnings Snapshot - CT Insider
Earnings call transcript: Abeona Therapeutics beats EPS forecast in Q1 2025 - Investing.com Nigeria
Abeona Therapeutics (ABEO) Target Price Raised Following FDA Approval and Strategic Sale | ABEO Stock News - GuruFocus
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seshadri Vishwas | Chief Executive Officer |
Jun 06 '25 |
Sale |
6.76 |
50,676 |
342,570 |
1,303,761 |
| O'Malley Brendan M. | SVP, General Counsel |
Jun 06 '25 |
Sale |
6.76 |
10,470 |
70,777 |
378,245 |
0.78%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):